Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
Date:11/17/2009

known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
2. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
6. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
7. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
8. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
9. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
11. Oncolytics Biotech(R) Inc. Announces Issuance of 32nd U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015  Cypher Genomics, Inc., a leading genome ... Corporation to apply Cypher,s Coral TM technology ... patient response to innovative medicines. The information generated ... patient access to the right medicine at the ... development and potentially inform new companion diagnostics.  ...
(Date:5/20/2015)... 2015 Research and Markets ( ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 ... Oral - Maxillofacial) - Global Industry Analysis, Size, ... report to their offering. The ... on the types of recombinant BMPs, applications, and ...
(Date:5/20/2015)... Cambridge, MA (PRWEB) May 20, 2015 ... quality transporter assay services for Drug-Drug Interactions (DDI), ... Rhenovia Pharma, a world leader in assessing impact ... Quantitative Systems Pharmacology supported by biosimulation, announced today ... The agreement allows both companies to expand their ...
(Date:5/20/2015)...  HOSTING, the leading provider of managed cloud ... official partner of the College of Healthcare ... Program. This unique collaboration leverages the HOSTING ... best practices derived from the CHIME professional ... enabling member healthcare organizations to achieve and ...
Breaking Biology Technology:Cypher Genomics Collaborates with Celgene Corporation to Identify Novel Genomic Biomarkers 2Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3HOSTING Named Partner of the CHIME Cooperative Member Services Program 2HOSTING Named Partner of the CHIME Cooperative Member Services Program 3
... ALS Lab Presents on Therapy Development StrategyCAMBRIDGE, Mass., ... (ALS TDI) has announced the 2009 launch of ... two-hour, interactive seminar is designed to inform and ... worldwide efforts to discover and develop effective treatments ...
... -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" ... operations in the,People,s Republic of China, today announced its ... 2009 ended December 31, 2008. , , ... -- Revenue was $32.9 million, up 24.1% ...
... potential) of stem cells and accelerates development of ... announces today the introduction of its GT(TM) Flow ... Summit to be held in New York, NY. ... validated, scalable technology for customizing the biological activity ...
Cached Biology Technology:Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 2MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies 3
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... WASHINGTON, DC A new analysis by the ... that the U.S. government has spent around $430 million ... the Department of Energy funding a majority of the ... European Union and three individual European countries the ...
... of dust and pollen in the atmosphere may make your ... in clouds, Colorado State University atmospheric scientists have discovered for ... to form precipitation in clouds is linked to the abundance ... study by Paul DeMott and Anthony Prenni, research scientists in ...
... If you think of diabetes onset like an elaborate ... Jolla Institute scientist has unmasked a previously unknown cellular player, ... is a hallmark of both type 1 and type 2 ... Jolla Institute for Allergy & Immunology, who led the team, ...
Cached Biology News:Amount of dust, pollen matters for cloud precipitation, climate change 2Amount of dust, pollen matters for cloud precipitation, climate change 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 2La Jolla Institute scientist leads team which discovers important new player in diabetes onset 3La Jolla Institute scientist leads team which discovers important new player in diabetes onset 4
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
... are specifically depleted of a single complement ... protein, the alternative and classical pathways are ... for the detection and quantitation of hemolytically ... used to assess complement activation in non-human ...
... the D-2000, except that it uses a deep-UV ... range and comes with a shutter (controlled via ... D-2000 Deuterium Light Source produces a powerful, stable ... of the light source are available, providing a ...
... The FLUOstar OPTIMA is a fully ... for life science labs in academia ... different measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
Biology Products: